U.S. markets closed
  • S&P Futures

    4,168.25
    +10.50 (+0.25%)
     
  • Dow Futures

    34,363.00
    +107.00 (+0.31%)
     
  • Nasdaq Futures

    13,349.25
    +45.75 (+0.34%)
     
  • Russell 2000 Futures

    2,233.50
    +8.00 (+0.36%)
     
  • Crude Oil

    66.45
    +0.18 (+0.27%)
     
  • Gold

    1,868.20
    +0.60 (+0.03%)
     
  • Silver

    28.56
    +0.28 (+0.99%)
     
  • EUR/USD

    1.2168
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    1.6400
    +0.0050 (+0.31%)
     
  • Vix

    19.72
    +0.91 (+4.84%)
     
  • GBP/USD

    1.4170
    +0.0033 (+0.23%)
     
  • USD/JPY

    109.1830
    -0.0170 (-0.02%)
     
  • BTC-USD

    44,807.90
    +697.69 (+1.58%)
     
  • CMC Crypto 200

    1,237.27
    +39.36 (+3.29%)
     
  • FTSE 100

    7,032.85
    -10.76 (-0.15%)
     
  • Nikkei 225

    28,402.64
    +577.81 (+2.08%)
     

Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
Nurix Therapeutics, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14th, 2021 at 11:45 a.m. ET.

The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. An archived copy of the webcast will be available on the Nurix website for approximately 30 days after the event.

About Nurix Therapeutics, Inc.
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com.

Contacts:

Investors:

Media:

Jason Kantor, Ph.D.

Elizabeth Wolffe, Ph.D.

Nurix Therapeutics, Inc.

Wheelhouse Life Science Advisors

jkantor@nurixtx.com

lwolffe@wheelhouselsa.com